Aerie Pharma (AERI) Receives a Buy from Mizuho Securities


Mizuho Securities analyst Salim Syed maintained a Buy rating on Aerie Pharma (AERI) on June 28 and set a price target of $77. The company’s shares closed on Friday at $29.55, close to its 52-week low of $28.81.

According to TipRanks.com, Syed is a 1-star analyst with an average return of -3.5% and a 45.6% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Atara Biotherapeutics, and Neon Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerie Pharma with a $75.43 average price target, representing a 155.3% upside. In a report issued on June 17, Cowen & Co. also maintained a Buy rating on the stock with a $105 price target.

See today’s analyst top recommended stocks >>

Based on Aerie Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $47.95 million. In comparison, last year the company had a GAAP net loss of $40.7 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts